2024 Annual Meeting | Industry Therapeutic Update from Eisai: An Option for Intervention in Early Alzheimer’s Disease: MCI Due to AD or Mild AD Dementia

Date Sunday 04/14/24

Time 11:45 AM - 12:45 PM MDT Add To Calendar

Location Colorado Convention Center | Bluebird 3A

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) David C. Weisman, MD

Topic(s) General Neurology, Aging, Dementia, and Behavioral Neurology

Learning Objectives An experienced thought leader will review pivotal Phase 3 data that led to US Food and Drug Administration (FDA) approval of an Alzheimer’s disease treatment and highlight key points of consideration to inform clinical practice and appropriate use.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
11:45 AM - 12:45 PM MDT	Speaker	Industry Therapeutic Update from Eisai: An Option for Intervention in Early Alzheimer’s Disease: MCI Due to AD or Mild AD Dementia

Faculty Disclosures
David C. Weisman, MD	Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Iqvia. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acumen. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lilly. The institution of Dr. Weisman has received research support from Eisai. The institution of Dr. Weisman has received research support from Biogen. The institution of Dr. Weisman has received research support from Roche. The institution of Dr. Weisman has received research support from Vivoryon. The institution of Dr. Weisman has received research support from Lilly. The institution of Dr. Weisman has received research support from Acumen. The institution of Dr. Weisman has received research support from Cerevel. The institution of Dr. Weisman has received research support from Sage. The institution of Dr. Weisman has received research support from Annovis. The institution of Dr. Weisman has received research support from Serono. Dr. Weisman has received intellectual property interests from a discovery or technology relating to health care. Dr. Weisman has received intellectual property interests from a discovery or technology relating to health care. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Temporary voting member with FDA.